본문으로 바로가기
현재 위치:
진료안내
진료과
의료진 소개
카카오 프린트

의료진 소개

권소영 의사
권소영 [ 소화기내과, 간센터, 소화기병센터(내시경실), 지방간클리닉, 이식클리닉 ]

간질환, 간암, 간이식

고맙습니다 진료예약
외래진료 외래진료 특수클리닉 특수클리닉
진료일정 05
진료일정(날짜, 오전, 오후)
날짜
오전
오후

논문

논문
  • Kim JW, Choi WH, Kwon SY, Yoo BC, Kim JH. MELD-GRAIL-Na Is a Better Predictor of Mortality Than MELD in Korean Patients with Cirrhosis.  Medicina. 2023 Mar;59(3):592. 
  • Kim JH, Choi WH, Kwon SY, Yoo BC, Kim JH. Switching from Tenofovir-Based Combination Therapy to Tenofovir Monotherapy in Multidrug-Experienced Chronic Hepatitis B Patients: a 5-Year Experience at Two Centers.  Antimicrobial Agents and Chemotherapy. 2022 Aug;66(8):e0027522. 
  • Yoo BC, Kwon SY. Tenofovir Alafenamide for Drug-Resistant Hepatitis B: A Randomized Trial for Switching from Tenofovir Disoproxil Fumarate.  Clinical Gastroenterology and Hepatology. 2022 Feb;20(2):423-37. 
  • Kim JH, Lee SY, Kwon SY, Sung IK, Park HS, Choi WH. Comparative study for predictability of type 1 gastric variceal rebleeding after endoscopic variceal ligation: High-frequency intraluminal ultrasound study.  World Journal of Clinical Cases. 2021 Dec 6;9(34):10566-75. 
  • Kwon BS, Choi WH, Kwon SY, Yoo BC, Park SJ, Kim JH. Comparison of the efficacy and safety of direct-acting antiviral therapy with or without hepatitis C-related hepatocellular carcinoma.  Korean Journal of Internal Medicine. 2021 Mar;36(2):292-304. 
  • Suh JW, Kwon BS, Lee TS, Kwon SY, Choi WH, Yoo BC, Shim CS, Yoon JM, Lee JH, Cheon YK. Prognostic impact of hepatitis B or C on intrahepatic cholangiocarcinoma.  Korean Journal of Internal Medicine. 2020 May;35(3):566-73. 
  • Kwon SY. Multiparametric MR Is a Valuable Modality for Evaluating Disease Severity of Nonalcoholic Fatty Liver Disease.  Clinical and Translational Gastroenterology. 2020 Apr;11(4):e00157. 
  • Kwon SY. Multiplexed Proteomic Approach for Identification of Serum Biomarkers in Hepatocellular Carcinoma Patients with Normal AFP.  Journal of Clinical Medicine. 2020 Feb;9(2):323. 
  • Lee HW, Park JY [et al.]. Long-term Outcomes of Antiviral Therapy in Patients with Advanced Chronic HBV Infection.  Clinical Gastroenterology and Hepatology. 2019 Dec;17(13):2811-2813. 
  • Choe WH, Kim K, Lee SY, Choi YM, Kwon SY, Kim JH, Kim BJ. Tenofovir is a more suitable treatment than entecavir for chronic hepatitis B patients carrying naturally occurring rtM204I mutations.  World Journal of Gastroenterology. 2019 Sep 7;25(33):4985-4998. 
  • Kim JD [et al.]. A Model to Predict 1-Month Risk of Transplant or Death in Hepatitis A-Related Acute Liver Failure.  Hepatology. 2019 Aug;70(2):621-629. 
  • Park HS, Choe WH, Han HS, Yu MH, Kim YJ, Jung SI, Kim JH, Kwon SY. Assessing significant fibrosis using imaging-based elastography in chronic hepatitis B patients: Pilot study.  World Journal of Gastroenterology. 2019 Jul 7;25(25):3256-3267. 
  • Lim YS, Gwak GY, Choi J, Lee YS, Byun KS, Kim YJ, Yoo BC, Kwon SY, Lee HC. Monotherapy with Tenofovir Disoproxil Fumarate for Adefovir-Resistant vs. Entecavir-Resistant Chronic Hepatitis B: a 5-Year clinical trial.  Journal of Hepatology. 2019 Jul;71(1):35-44. 
  • Park ES, Lee AR, Kim DH, Lee JH [et al.]. Identification of a quadruple mutation that confers tenofovir resistance in chronic hepatitis B patients.  Journal of Hepatology. 2019 Jun;70(6):1093-1102. 
  • Kim AR, Park E, Kwon SY, Park SJ, Kim YJ, Yoo BC, Choe WH, Kim JH, Hwang JH, Park SW, Kim YJ, Park HS, Yu MH, Jeon HJ. Efficacy and Safety of Combined Radiofrequency Ablation with Transarterial Chemoembolization in Patients with Barcelona Clinic Liver Cancer Stage A Hepatocellular Carcinoma Ineligible for Curative Treatment.  Korean Journal of Gastroenterology. 2019 Mar;73(3):167-176. 
  • Choe WH, Kwon SY. Nucleos(t)ide Analogue Treatment for Adult Patients with HBeAg-positive Chronic Infection with Genotype C Hepatitis B Virus: A Nationwide Real-life Study.  Journal of Infectious Diseases. 2017 Dec 1;216(11):1407-14. 
  • Kwon SY, Yoo BC. Monotherapy with Tenofovir Disoproxil Fumarate for Multiple Drug-Resistant Chronic Hepatitis B: 3-Year Trial..  Hepatology. 2017 Sep;66(3):772-83. 
  • Lim YS, Byun KS, Yoo BC, et al. Tenofovir monotherapy versus tenofovir and entecavir combination therapy in patients with entecavir-resistant chronic hepatitis B with multiple drug failure: results of a randomised trial.  Gut. 2015 . 
  • Lee CI, Kwon SY, Kim JH, et al. Efficacy and safety of tenofovir-based rescue therapy for chronic hepatitis B patients with previous nucleo(s/t)ide treatment failure.  Gut Liver. 2014;8:64-9. 
  • Kwon SY, Park SH, Yeon JE, et al. Clinical characteristics and outcomes of acute hepatitis a in Korea: a nationwide multicenter study.  J Korean Med Sci. 2014;29:248-53. 
  • Ahn SH, Park YK, et al. The impact of the hepatitis B virus polymerase rtA181T mutation on replication and drug resistance is potentially affected by overlapping changes in surface gene.  J Virol. 2014;88:6805-18. 
  • Kim JJ, Kim JH, Koo JK, et al. The Refit model for end-stage liver disease-Na is not a better predictor of mortality than the Refit model for end-stage liver disease in patients with cirrhosis and ascites.  Clin Mol Hepatol. 2014;20:47-55. 
  • Kim HJ, Kim JH, Choe WH, et al. Alcoholic fatty liver disease elevates estimated coronary heart disease risk to levels comparable with those of nonalcoholic fatty liver disease in the Korean population: a cross-sectional study.  Clin Mol Hepatol. 2014;20:154-61. 
  • Choi YJ, Kim JH, Koo JK, et al. Prevalence of renal dysfunction in patients with cirrhosis according to ADQI-IAC working party proposal.  Clin Mol Hepatol. 2014 ;20:185-91. 
  • Choe WH, Kim YJ, Park HS, et al. Short-term interval combined chemoembolization and radiofrequency ablation for hepatocellular carcinoma.  World J Gastroenterol. 2014;20:12588-94. 
  • Kim JH, Moon HW, Ko SY, et al. Hepatitis B surface antigen levels at 6 months after treatment can predict the efficacy of lamivudine-adefovir combination therapy in patients with lamivudine-resistant chronic hepatitis B.  Clin Mol Hepatol. 2014;20:274-82. 
  • Kim JH, Yeon JE, Baik SK, et al. Genotypic shift of the hepatitis A virus and its clinical impact on acute hepatitis A in Korea: a nationwide multicenter study.  Scand J Infect Dis. 2013;45:811-8. 
  • Kim BH, Kim YJ, Jeong SH, et al. Clinical features of autoimmune hepatitis and comparison of two diagnostic criteria in Korea: a nationwide, multicenter study.  J Gastroenterol Hepatol. 2013;28128-34. 
  • Park ES, Park YK, Shin CY, et al. Hepatitis B virus inhibits liver regeneration viaepigenetic regulation of urokinase-type plasminogen activator.  Hepatology. 2013;58:762-76. 
  • Kim BK, Ko SY, Kwon SY, et al. Virological Response and Muscular Adverse Events during Long-Term Clevudine Therapy in Chronic Hepatitis B Patients.  Hepat Mon. 2013;1;13:e6056. 
  • Kim JH, Choi YJ, Moon HW, et al. HBsAg level and clinical course in patients with chronic hepatitis B treated with nucleoside analogue: five years of follow-up data.  Clin Mol Hepatol. 2013;19:409-16. 
  • Kim JH, Kwon SY, Lee YS, et al. Virologic response to therapyincreases health-related quality of life for patients with chronic hepatitis B.  Clin Gastroenterol Hepatol . 2012;10:291-296. 
  • Ko SY, Choe WH, Kwon SY, et al. Long-term impact of entecavir monotherapy in chronic hepatitis B patients with a partial virologic response to entecavir therapy.  Scand J Gastroenterol. 2012;47:1362-7. 
  • Ko SY, Kim BK, Kwon SY, et al. Clonal evolution of hepatitis B virus polymerase gene mutations during lamivudine-adefovir combination treatment.  World J Gastroenterol. 2012;8:6437-46. 
  • Choi HJ, Ko SY, Choe WH, et al. Clinical features of acute viral hepatitis B in Korea: a multi-center study.  Korean J Hepatol. 2011;17:307-12.